Newer antidepressants have one major advantage over their older tricyclic cousins - namely, they cause fewer of the anticholinergic adverse events that discourage patients from taking their medication. And, despite higher upfront costs, the newer agents have been associated with lower total depression treatment costs than the tricyclics. But when it comes to choosing between the range of newer antidepressants available, there is very little research comparing the relative economic benefits of these agents. Now, however, a new study has revealed that nefazodone has the lowest depression-related treatment costs of six new antidepressants.1The study was presented at a poster session of the 5th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research [Arlington, Virginia, US; May 2000].